SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Investors are weighing the high probability of a Federal Reserve rate hike against concerns over surging oil prices and volatile Treasury yields, leading to cautious and bearish sentiment ahead of the FOMC decision. The conversation is further dominated by debates regarding the impact of proposed artificial intelligence development slowdowns on tech stocks.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The community is debating the potential impacts of a Federal Reserve rate hike following reports of a 90% probability of an increase, while also reacting to conflicting signals regarding artificial intelligence development and rising Treasury yields.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as traders anticipate positive guidance updates and upcoming trial data, following recent healthcare conference appearances. Community sentiment remains bullish, with investors speculating on potential institutional accumulation and the company's long-term value driven by its TIL therapy platform.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as traders debate whether the stock's recent price consolidation represents institutional accumulation or manipulation, with many investors maintaining a bullish long-term outlook based on fundamental growth and free cash flow despite the lack of immediate upward momentum. While some traders expressed frustration over the stock's failure to sustain rallies and its sensitivity to interest rate concerns and analyst downgrades, others highlight strong technical indicators and upcoming holiday season e-commerce tailwinds as catalysts for a potential reversal.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as traders react to rising long-term Treasury yields and shifting expectations for a potential Federal Reserve rate hike. The conversation remains divided, with some investors debating whether to buy the dip in bonds while others anticipate further downside due to ongoing inflationary pressures and energy market volatility.

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

Gold is facing pressure as traders react to rising US Treasury yields and shifting market expectations regarding interest rate decisions, leading to a period of uncertainty. While some investors remain bullish on gold as a hedge against long-term debt concerns, many in the community are closely monitoring macro data and bond market volatility for signals on the next price trend.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

Traders are actively debating the structural decay of the instrument, with many expressing frustration over its failure to track volatility spikes during periods of market stress, frequently labeling it a "scam" due to consistent performance degradation. While some investors remain bearish on the broader market and hold positions for potential tail-risk events, others warn that its design as a short-term trading tool makes long-term holding highly unprofitable.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Quantinuum's shares are experiencing volatility following its initial public offering as investors weigh the company's long-term potential in the quantum computing sector against concerns regarding its high valuation and lack of significant current revenue. While some traders are focused on the stock as a long-term play backed by strategic partners, others remain skeptical, citing broader market weakness and the company's early-stage financial profile.

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clover Health is trending as traders speculate on a potential strategic partnership with Humana, fueled by recent job postings and industry developments regarding the company's Counterpart Assistant platform. While retail sentiment remains overwhelmingly bullish, there is ongoing debate regarding the timeline for revenue realization and frustration over the stock's recent price consolidation despite these perceived tailwinds.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as traders discuss the company's recent definitive agreement to receive up to $100 million in government funding to accelerate quantum research, a catalyst that has sparked debate over the potential for dilution versus long-term growth. The stock is also being traded in tandem with other quantum computing peers amid high volatility, with investors monitoring the company's technical milestones and insider activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 20.4% in April

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) was the target of a large drop in short interest in April. As of April 15th, there was short interest totaling 12,887 shares, a...

Molecular Partners (NASDAQ:MOLN) Given "Buy" Rating at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and issued a $13.00 price target on shares of Molecular Partners in a report on Wednesday...

Molecular Partners (NASDAQ:MOLN) Stock Price Up 5%  - Still a Buy?

Molecular Partners (NASDAQ:MOLN) Trading Up 5% - Time to Buy...

Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Drops By 18.9%

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) was the recipient of a large decrease in short interest during the month of March. As of March 13th, there was short interest...

HC Wainwright Brokers Increase Earnings Estimates for MOLN

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Molecular Partners in a...

Molecular Partners' (MOLN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $13.00 price objective on shares of Molecular Partners in a research note on Monday...

Molecular Partners (NASDAQ:MOLN) Issues Quarterly Earnings Results

Molecular Partners (NASDAQ:MOLN - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus...

Will Petrobras Pull Off Q4 Earnings Beat on Strong Production?

PBR gears up for fourth-quarter results as pre-salt output hits 3,109 MBOE/d, but refining outages and weaker fuel production may weigh on margins.

Molecular Partners (MOLN) to Release Quarterly Earnings on Thursday

Molecular Partners (NASDAQ:MOLN) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...

Molecular Partners (NASDAQ:MOLN) Stock Price Down 1.5% - Should You Sell?

Molecular Partners (NASDAQ:MOLN) Trading Down 1.5% - Here's What Happened...

Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274, and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners AG - ADR

Neutral Sentiment

50bps hike

25bps hike

No change

25bps cut

The Federal Reserve's September FOMC meeting concludes Wednesday, September 16, with a rate decision due at 2:00 PM ET, following Tuesday's CPI report that showed inflation still running above the Fed's 2% target. What do you think the Fed decides at this week's FOMC meeting? Vote and explain your reasoning in the comments.

The Fed&#39;s rate decision comes Wednesday at 2PM ET. What do you think happens?

Stocktwits

The Fed's rate decision comes Wednesday at 2PM ET. What do you think happens?

Current Price	$4.02
Prev Close	$4.18
Open	$4.15
Dividend Yield	0.00%
50-Day Moving Average	$4.15
Beta	0.66
Avg. Volume	1,430.63
PE Ratio	-2.35

52-Week High	$5.36
52-Week Low	$3.53
Market Capitalization	$153.99M
EPS (Annual)	-$1.99
Price to Book	2.12
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

MOLN Fundamentals